<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04946474</url>
  </required_header>
  <id_info>
    <org_study_id>M2019412</org_study_id>
    <nct_id>NCT04946474</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the Combination of Symptoms and Symptoms With General Treatment for Acute Hemorrhagic Stroke</brief_title>
  <official_title>Clinical Evaluation and Study on the Combination of Disease and Syndrome With General Treatment for Acute Hemorrhagic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective To evaluate whether Xingnaojing injection combined with Naoxueshu oral liquid can&#xD;
      significantly improve the clinical outcome of patients with intracerebral hemorrhage.&#xD;
&#xD;
      Secondary objectives included to evaluate whether combined application of Xingnaojing&#xD;
      injection and Naoxueshu oral liquid can promote hematoma absorption or reduce perihematoma&#xD;
      cerebral edema in patients with intracerebral hemorrhage&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective To evaluate whether Xingnaojing injection combined with Naoxueshu oral liquid can&#xD;
      significantly improve the clinical outcome of patients with intracerebral hemorrhage.&#xD;
&#xD;
      Secondary objectives included to evaluate whether combined application of Xingnaojing&#xD;
      injection and Naoxueshu oral liquid can promote hematoma absorption or reduce perihematoma&#xD;
      cerebral edema in patients with intracerebral hemorrhage Statistical Methods: The main&#xD;
      effective outcomes will be based on a generalized linear model and adjusted for associated&#xD;
      confounders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>self-care</measure>
    <time_frame>after 90 days</time_frame>
    <description>90 days of self-care (mRS 0-2 points)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>on day 14 of onset</time_frame>
    <description>NIHSS score improvement on day 14 of onset</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Acute Hemorrhagic Stroke</condition>
  <arm_group>
    <arm_group_label>Xingnaojing injection + Shuxuetong oral liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Xingnaojing injection simulation agent + Naoxueshu oral liquid simulation agent treatment was given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xingnaojing injection + Shuxuetong oral liquid</intervention_name>
    <description>Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).</description>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_label>Xingnaojing injection + Shuxuetong oral liquid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ① It meets the diagnostic criteria of primary cerebral hemorrhage.&#xD;
&#xD;
               -  Within 72 hours of onset.&#xD;
&#xD;
                    -  National Institutes of Health Stroke Scale (NIHSS) score ≥4 points.&#xD;
&#xD;
                       ④ Glasgow Coma Scale (GCS) score &amp;gt; Eight points.&#xD;
&#xD;
                       ⑤ Age 18-80. Patient or legal representative informed consent, and sign&#xD;
                       informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) known to Xingnaojing, cerebral hemorrhage or related drug ingredients allergic.&#xD;
&#xD;
               -  The patients with previous stroke history and remaining sequelae affected the&#xD;
                  outcome assessment, that is, the modified Ranking scale (MRS) score before the&#xD;
                  onset of stroke was ≥2 points.&#xD;
&#xD;
                  (3) known by amyloid cerebrovascular disease, vascular malformation, aneurysm,&#xD;
                  blood coagulation dysfunction, anticoagulation and antiplatelet drug treatment,&#xD;
                  thrombolysis therapy, bleeding after infarction after conversion, haematology,&#xD;
                  moyamoya disease, primary or metastatic tumor, venous sinus thrombosis, and&#xD;
                  vascular inflammation caused by clear etiology of patients with cerebral&#xD;
                  hemorrhage or primary intraventricular hemorrhage.&#xD;
&#xD;
        (Note: &quot;After anticoagulant or antiplatelet therapy&quot; refers to patients with intracerebral&#xD;
        hemorrhage following anticoagulant and antiplatelet therapy, and these patients were&#xD;
        excluded from this study.) (4) Patients with traumatic cerebral hemorrhage. (5) patients&#xD;
        with active gastrointestinal ulcer or other definite tendency of rebleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Yniversity Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2021</study_first_posted>
  <last_update_submitted>June 27, 2021</last_update_submitted>
  <last_update_submitted_qc>June 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

